EF Hutton analyst Constantine Davides reiterated a Buy rating on VolitionRX (VNRX – Research Report) today and set a price target of $6.00. The company’s shares opened today at $1.44.
According to TipRanks, Davides is an analyst with an average return of -15.0% and a 29.63% success rate. Davides covers the Healthcare sector, focusing on stocks such as VolitionRX, Acasti Pharma, and Nemaura Medical.
VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.30 and a one-year low of $1.31. Currently, VolitionRX has an average volume of 173.7K.
Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VNRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.
Read More on VNRX:
- VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
- VolitionRx 4.3M share Spot Secondary priced at $1.75
- VolitionRx announces common stock offering, no amount given
- VolitionRx downgraded to Hold at Benchmark on valuation
- VolitionRx downgraded to Hold from Buy at Benchmark
